As of the latest Form 4 filed May 26, 2026.
What Acrivon Therapeutics, Inc. Common Stock insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 35 most recent filings for ACRV.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | 2026-05-21 | Blume-Jensen Peter President and CEO | FTax | −13.7K | $1.79 | $24.6K | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | RA CAPITAL MANAGEMENT, L.P. Director | AAward | +9.37K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | TOMSICEK MICHAEL JOHN Director | AAward | +9.37K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Shacham Sharon Director | AAward | +9.37K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Palani Santhosh Director | AAward | +9.37K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Magovcevic-Liebisch Ivana Director | AAward | +9.37K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | DiRocco Derek Director | AAward | +9.37K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | BAUM CHARLES M Director | AAward | +9.37K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Peterson Katharine Chief Accounting Officer | AAward | +14.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Mirza Mansoor Raza Chief Medical Officer | AAward | +38.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Miller Mary Chief Legal Officer | AAward | +49.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Levy Adam D. Chief Financial Officer | AAward | +46.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Gamelin Erick Chief Development Officer | AAward | +38.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Devroe Eric Chief Operating Officer | AAward | +73.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Blume-Jensen Peter President and CEO | AAward | +72.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Blume-Jensen Peter, President and CEO | AAward | +180K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Peterson Katharine Chief Accounting Officer | FTax | −99.00 | $1.92 | $190.08 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Miller Mary Chief Legal Officer | FTax | −184.00 | $1.92 | $353.28 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Gamelin Erick Chief Development Officer | FTax | −404.00 | $1.92 | $775.68 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Devroe Eric Chief Operating Officer | FTax | −613.00 | $1.92 | $1.18K | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Blume-Jensen Peter President and CEO | FTax | −490.00 | $1.92 | $940.80 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Blume-Jensen Peter, President and CEO | FTax | −1.25K | $1.92 | $2.41K | No | Form 4 ↗ |
| 2026-04-23 | 2026-04-22 | RA CAPITAL MANAGEMENT, L.P. Director | AAward | +3.89M | $1.80 | $7.00M | No | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Miller Mary Chief Legal Officer | FTax | −558.00 | $1.78 | $993.24 | No | Form 4 ↗ |
| 2026-02-24 | 2026-02-21 | Blume-Jensen Peter President and CEO | FTax | −14.3K | $1.53 | $21.8K | No | Form 4 ↗ |
| 2026-02-18 | 2026-02-14 | Peterson Katharine Chief Accounting Officer | FTax | −116.00 | $1.63 | $189.08 | No | Form 4 ↗ |
| 2026-02-18 | 2026-02-14 | Miller Mary Chief Legal Officer | FTax | −217.00 | $1.63 | $353.71 | No | Form 4 ↗ |
| 2026-02-18 | 2026-02-14 | Gamelin Erick Chief Development Officer | FTax | −471.00 | $1.63 | $767.73 | No | Form 4 ↗ |
| 2026-02-18 | 2026-02-14 | Devroe Eric Chief Operating Officer | FTax | −723.00 | $1.63 | $1.18K | No | Form 4 ↗ |
| 2026-02-18 | 2026-02-14 | Blume-Jensen Peter President and CEO | FTax | −579.00 | $1.63 | $943.77 | No | Form 4 ↗ |
| 2026-02-18 | 2026-02-14 | Blume-Jensen Peter, President and CEO | FTax | −1.30K | $1.63 | $2.12K | No | Form 4 ↗ |
| 2026-01-21 | 2026-01-17 | Miller Mary Chief Legal Officer | FTax | −659.00 | $1.98 | $1.30K | No | Form 4 ↗ |
| 2026-01-16 | 2026-01-14 | Blume-Jensen Peter President and CEO | PPurchase | +49.0K | $1.68 | $82.1K | No | Form 4 ↗ |
| 2026-01-16 | 2026-01-14 | Levy Adam D. Chief Financial Officer | PPurchase | +8.83K | $1.70 | $15.0K | No | Form 4 ↗ |
| 2026-01-15 | 2026-01-13 | Devroe Eric Chief Operating Officer | PPurchase | +10.0K | $1.72 | $17.2K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ACRV’s full analysis or the market-wide insider trading feed. The tabs above jump to ACRV’s other SEC data.
Source: SEC Form 4 filings for ACRV, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.